Clinical Nutrition: Preoperative abdominal fat distribution and systemic immune inflammation in patients with non-muscular invasive bladder cancer are associated with the response to BCG immunotherapy in the bladder

Bladder cancer is a very common malignant tumor of the urinary system, which mostly occurs in middle-aged and elderly people
.

There are many factors that can lead to bladder cancer

Bladder cancer is a very common malignant tumor of the urinary system, which occurs mostly in middle-aged and elderly people

 

This study retrospectively analyzed the clinicopathological data of 184 intermediate and high-risk NMIBC cases who underwent transurethral bladder tumor resection (TURBT) and intravesical BCG immunotherapy from December 2014 to April 2021
.

All patients were divided into BCG responders and non-responders

 

The results of the study showed that compared with those who did not respond to BCG, the RFS of those who responded to BCG increased significantly
.

Multivariate Cox regression analysis showed that low grade, pTa staging, non-CIS, low relative visceral fat area (rVFA) and low systemic immune inflammation index (SII) are independent prognostic factors for increased RFS after BCG immunotherapy in the bladder

 

From this, the authors concluded that low tumor grade, pTa staging, non-CIS, low preoperative rVFA and low SII are important independent predictors of the response to BCG immunotherapy in the bladder, and the prognosis of patients with NIMBC is better.
Related
.

The addition of SII and rVFA before surgery can significantly improve the prediction efficiency

From this, the authors concluded that low tumor grade, pTa staging, non-CIS, low preoperative rVFA and low SII are important independent predictors of the response to BCG immunotherapy in the bladder, and the prognosis of patients with NIMBC is better.

 

Original source:

Zhi-Bin Ke.

Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer in this message